Solara Active Pharma Sciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.6%−0.4%−10.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−9.5%+316.7%−171.1%
−18.6%+153.9%−974.5%
−1,472.2%+100.1%−2,449.3%
−1,300.0%+100.1%−2,458.8%
+4.5%−5.1%−18.9%
+14.5%+17.1%−37.7%
−28.2%+95.5%−30.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹2,910 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-10.7-0.4+6.6—
EBITDA Growth—-171.1+316.7-9.5—
EBIT Growth—-974.5+153.9-18.6—
Net Income Growth—-2,449.3+100.1-1,472.2—
EPS Growth—-2,458.8+100.1-1,300.0—
Total Assets Growth—-18.9-5.1+4.5—
Total Equity Growth—-37.7+17.1+14.5—
Cash from Operations Growth—-30.3+95.5-28.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.